/ /

  • linkedin
  • Increase Font
  • Sharebar

    Time for a paradigm shift in the treatment of DME


    Happy patients = happy doctor

    The implant has proven its efficacy and safety both clinically and personally to me based on my patient outcomes. When anti-VEGF therapy has limited efficacy, we now have an excellent long-term treatment option that may lift the burden of frequent office visits and costly anti-VEGF injection treatments. Patients whom I have treated with the long-term therapy enjoy comparable or better visual outcomes than those treated with anti-VEGF. In follow up visits, these patients continue to do well and are happy. When my patients are happy, I am happy.


    Case study

    This is one of my recent patients who nicely demonstrates not only the excellent clinical efficacy but also the ability of a treatment to improve a patient’s lifestyle and allow them to live life to the fullest.

    A 65-year old pseudophakic patient presented to me with a history of battling DME for five years in the right eye. The patient had received multiple treatments in the past including intravitreal Triesence (Alcon) and Ozurdex (Allergan, Inc.) with no rise in IOP, focal laser, and monthly Aflibercept (Eylea), Ranibizumab (Lucentis), and Bevacizumab (Avastin) intravitreal injections.     

    The patient reported that the monthly injection regiment was detrimental to his lifestyle and he felt that he is burdening his family with the need for frequent transportation. He inquired about longer lasting treatments, thus I provided him with the option of the long-term implant.

    Clinical course

    Joshua Mali, MD
    Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results